REG - Convatec Group PLC - Professor Constantin Coussios steps down

ConvaTecAnnouncement

Yesterday 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM1998Aa&default-theme=true

RNS Number : 1998A  Convatec Group PLC  13 April 2026

Convatec Group Plc
("Convatec" or "the Company")

 

Professor Constantin Coussios OBE steps down from

Board of Directors and AGM resolution change

 

London, UK, 13 April 2026 - Convatec congratulates Professor Constantin
Coussios OBE on his appointment as Pro-Vice-Chancellor for Innovation at the
University of Oxford. He will be stepping down as a Non-Executive Director of
Convatec Group Plc with effect from 30 April 2026 as he takes up his new
appointment.

 

Since his appointment in September 2020, Professor Coussios has worked closely
with the Board, senior management and Convatec's Chief Science, Innovation
& Quality Officer Dr Divakar Ramakrishnan to transform and re-shape
Convatec's research and development capabilities, accelerate new product
development, and position the Company for sustained, innovation-led growth.
Over the past six years, Convatec has completed several transformative
strategic acquisitions, its internal new product development cycle time has
been compressed by c.30%, and the vitality index has strengthened steadily
from c.10% to c.30%, with 16 new product launches underway since 2022.

 

Dr John McAdam CBE, Chair of the Board, said: "Over the past six years,
Constantin has been key to the successful delivery of Convatec's
innovation-led turnaround and we thank him for his unique contribution. We now
have the strongest pipeline of innovative new products in Convatec's history.
As Constantin takes up his exciting new role at the University of Oxford,
together with all Board colleagues, we wish him every continued success for
the future."

 

As the Company's AGM Notice has already been issued, the Company confirms that
the resolution to re-elect Professor Coussios as a Non-Executive Director of
the Company (resolution number 9) is now withdrawn. The withdrawal of
resolution number 9 does not otherwise affect the validity of the Notice of
Meeting, the proxy form or any proxy votes already submitted on other proposed
resolutions. The numbering of all other proposed resolutions at the AGM will
remain unchanged.

 

This announcement is made in accordance with Listing Rule 6.4.6.

 

Enquiries

Company Secretariat: CoSec@convatec.com (mailto:CoSec@convatec.com)

Media: mediarelations@convatec.com (mailto:mediarelations@convatec.com)

Analysts & investors: ir@convatec.com (mailto:ir@convatec.com)

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

Classification: 3.1 Additional regulated information required to be disclosed
under the laws of the United Kingdom

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than
10,000 colleagues, we provide products and services in around 90 countries,
united by a promise to be forever caring. Our solutions provide a range of
benefits, from infection prevention, treatment for hard to heal wounds,
at-risk skin and ulcerated tissue to supporting debilitating conditions,
improved patient outcomes and reduced care costs. Convatec's revenues in 2025
were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more please visit http://www.convatecgroup.com
(https://www.convatecgroup.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUBACUPQURW



            Copyright 2019 Regulatory News Service, all rights reserved